uniQure N.V. reported its financial results for the fourth quarter and full year of 2024 on February 27, 2025, highlighting significant clinical and operational progress. The company's cash, cash equivalents, and investment securities stood at $367.5 million as of December 31, 2024. Including $80.7 million in net proceeds from a recently completed follow-on offering, the proforma cash position was approximately $448 million, expected to fund operations into the second half of 2027.
For the full year 2024, total revenue was $27.1 million, an increase from $15.8 million in 2023, driven by higher license and collaboration revenue, despite a decrease in contract manufacturing revenue following the divestiture of the Lexington facility. The net loss for the full year 2024 narrowed to $239.6 million, or $4.92 per share, compared to a net loss of $308.5 million, or $6.47 per share, in 2023.
Research and development expenses decreased to $143.8 million for the full year 2024 from $214.9 million in 2023, primarily due to reduced employee-related expenses and changes in contingent consideration. Selling, general, and administrative expenses also decreased to $52.7 million from $74.6 million, reflecting cost reduction efforts from the company-wide restructuring and facility divestiture.
On the clinical front, uniQure achieved alignment with the FDA on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease and initiated BLA-readiness activities. Enrollment was completed in the third cohort of the AMT-130 Phase I/II study. Additionally, dosing began for AMT-260 in mTLE, and enrollment was completed for the first cohorts of AMT-191 in Fabry disease and AMT-162 in SOD1-ALS, with favorable IDMC recommendations to proceed with dosing the second cohorts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.